Новые возможности современных макролидов при лечении острых респираторных инфекций

1. Gwaltney JN, Bisno AI. Pharyngitis. Principles and practice of infectious diseases. GL.Mandel, R.Dolan, JE.Bennett (eds). 5th ed. New York: Churchill Livingstone 2000; 656–62.
2. Cooper RJ, Hoffman JR, Bartlett JG et al. Principles of appropriate antibiotic use foe acute pharyngitis in adults: background. Ann Intern Med 2001; 134: 509–17.
3. Nyman M, Algupalli R, Stromberg S, Forsgren A. Antibody response to Arcanobacterium haemolyticum infections in humans. J Infect Dis 1997; 175: 1515–8.
4. Bisno AL. Acute pharyngitis. N Engl J Med 2001; 344 (3): 205–11.
5. Neu HC. Otitis media: antibiotic resistance of causative and treatment alternatives. Pedidatr Infect Dis J 1995; 14: 51–6.
6. Turner D, Leibovitz E, Aran A et al. Acute otitis media in infants younger than two months of age: microbiology, clinical presentation and theraputic approach. Pediatr Infect Dis J 1991; 10: 425–7.
7. Gwaltney JM. Sinusitis. Mandel, Douglas and Bennett's Prinsiples and Practice of Infectious Disease. GN.Mandel, JE.Bennet, R.Dolin (eds). 4th ed. New York, Churchill Livingstone Inc. 1995; Ch. 44.
8. Hadley JA, Siegert R. Clinicial's Manual on Rhinosinusitis. London. Science Press Ltd., 2004.
9. Bartlett JG, Dowell SF, Mandell LA et al. Guidelines from the Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 21: 661–5.
10. File TM, Tan S. International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides. Drugs 2003; 63: 181–205.
11. Anzueto A. Contemporary Diagnosis and Management of Bronchitis. 2nd ed. AMM Co., Inc, USA. 1999.
12. Eller J, Ede A, Schaberg T et al. Infective exacerbation of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542–8.
13. Kawamura-Sato K, Iinuma Y, Hasegawa T et al. Postantibiotic suppression effect of macrolides on the expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. J Infect Chemother 2001; 7: 51–4.
14. Wozniak DJ, Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 2004; 125: 62–9.
15. Nalka Y, Jansch L, Bredenbruch F et al. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginisa PAO1: a global approach. Antimicrob Agents Chemother 2006; 50: 1680–8.
16. Culic O, Erakovic V, Pamham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429: 209–29.
17. Woo PC, Lau SK, Yuen KY. Macrolides as immunomodulatory agents. Curr Med Chem Anti Inflammatory Anti Allergy Agents 2002; 1: 131–41.
18. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004; 125 (Suppl.): 41S–51S.
19. Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother 1995; 39: 1688–90.
20. Tagaya E, Tamaoki J, Kondo M, Nagai A. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest 2002; 122: 213–8.
21. Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997; 155: 2018–23.
22. Pechere JC. New perspective on macrolide antibiotics. Intern J Antimicrob Agents 2001; 18 (Suppl. 1): 92–8.
23. Amsden JW. Pharmacological consideration in the emergence of resistance. J Antimicrob Agents 1999; Suppl. 11: 17–23.
24. Dunn CJ, Barradell LB. Azithromycin: a review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 1996; 51: 483–505.
25. Hopkins S. Clinical toleration and safety of azithromycin in adults and children. Rev Contemp Pharmacother 1995; 5: 383–9.
26. Schito GC, Debbia EA, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project. J Antimicrob Chemother 2000; 46 (Suppl. T1): 3–9.
27. Huff J, White A, Power E et al. 10-year trends in penicillin- and erythromycin-resistant S.pneumoniae for 5 European countries and the USA. The Alexander Project [abstract C2-1624]. In: Abstracts from the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA: American Society of Microbiology, 2002; 108.
28. Schito GC. Is antimicrobial resistance also subject to globalization? Clin Microbial Infect 2002; 8 (Suppl. 3): 1–8.
29. Козлов Р.С., Кречикова О.И., Сивая О.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России: результаты проспективного многоцентрового исследования (фаза А проекта ПеГАС-1). Клин. микробиол. и антимикробная химиотер. 2002; 3: 267–77.
30. PROTEKT Study Database. Feb. 2001 (http:http://w.w.w.protekt.org).
31. Cornaglia G, Fontana R. Epidemiological survey of bacterial rasistance in upper respiratory tract infections in Italy. Int J Antimicrob Agents 2000; 16: 259–62.
32. Melo-Cristino J, Fernandes ML. Streptococcus pyogenes isolated in Portugal: macrolide resistance phenotypes and correlation with T types. Portuguese Surveillance Group for Study of Respiratory Pathogenes. Microb Drug Resist 1999; 5: 219–25.
33. Alos JI, Aracil B, Torres C et al. High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998, Spanish group for the study of Infection in the Primary Health Care Setting. J Antimicrob Chemother 2000; 45: 605–9.
34. Baquero F, Garcia-Rodriguez JA, de Lomas JC, Aguilar L. Antimicrobial resistance of 914 beta-hemolytic streptococci isolated from pharyngeal swabs in Spain: results of 1-year (1996–1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogenes. Antimicrob Agents Chemother 1999; 43: 178–80.
35. Kaplan EL, Johnson DR, Del Rosario MC, Horn DL. Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997. Pediatr Infect Dis 1999; 18: 1069–72.
36. de Azavedo JC, Yeung RH, Bast DJ et al. Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada. Antimicrob Agents Chemother 1999; 43: 2144–7.
37. Козлов Р.С., Сивая О.В., Шпынев Л.В. и др. Антибиотикорезистентность Streptococcus pyogenes в России: результаты многоцентрового проспективного исследования ПеГАС-1. Клин. микробиол. и антимикробная химиотер. 2005; 2: 154–66.
38. Сидоренко С.В. Проблемы этиотропной терапии внебольничных инфекций дыхательных путей. Consilium Medicum 2002; 1: 4–10.
39. Чучалин А.Г., Синопальников А.И., Яковлев С.В. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике (пособие для врачей). Клин. микробиол. и антимикроб. химиотер. 2003; 3: 198–224.
40. Jones ME, Blosser-Middleton RS, Critchley IA et al. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001. Clin Microbiol Infect 2003; 9: 590–9.
41. Welsh L, Gaydos C, Quinn TC. In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. Antimicrob Agents Chemother 1996; 40: 212–4.
42. Weidenman MS, Bass JB, Camplett GD et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnose, assessment of severity and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418–26.
43. Mandel LA, Marrie TJ, Grossman RE et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31: 383–421.
44. Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138–80.
45. Niederman MS, Mandell LA, Anzueto A et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Resp Crit Care Med 2001; 163: 1730–54.
46. Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и др. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике. М.:ООО "Издательский дом "М-Вести", 2006.
47. Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community-acquired pneumonia: meta-analysis. BMJ 2005; 330 (7489): 456–64.
48. Garcia EV, Mensa J, Martinez JA et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Infect Dis 2005; 24: 190–5.
49. Watere GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161: 1837–42.
50. Plouffe J, Schwartz DB, Kolokathis A et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumoniae. Antimicrobial Agents Chemother 2000; 44: 1796–802.
51. Mensa J, Trilla A. Should patients with acute exacerbation of chronic bronchitis be treated with antibiotics? Clin Microbiol Infect 2006; 12 (Suppl. 3): 42–54.
52. Weiss K, Restiery C, Cuach C et al. Changing susceptibilities of invasive Streptococcus pneumoniae strains to penicillin, cefuroxime, erythromycin and clarithromycin from 1990 to 1998 in Montreal, Canada. Abstr. Of 5-th ICMAS & KO, Seville. 2000; 01–05.
53. el Moussaaoi R, de Borgie CA, van den Broek P et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomized, double study. Brit Med J 2006; 332: 1355.
54. Kozyrskkyj AL Hildes-Ripstein GE, Longstaffe SE et al. Treatment of acute otitis media with a shortened course of antibiotics: A meta-analysis. JAMA 1998; 279 (21): 1736–42.
55. Henry DC, Riffer E, Sokol WN et al. Comparison of azithromycin and amoxicillin/clavulanate in the treatment of acute ENT infections. Antimicrob Agents Chemother 2003; 47: 2770–4.
56. Biebuyck XA. Comparison of azithromycin and co-amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults. J Intern Med Res 1996; 24: 407–18.
57. Drehobl MA, De Salvo MC, Breen JD. Single-dose azythromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 2005; 128 (4): 2230–7.
58. Breen JD, Zervos MJ, Jorgensen D, Goodrich JM. Single-dose azithromycin microspheres versus levofloxacin for the treatment of acute exacerbation of chronic bronchitis (AECB). Proceedings of 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2005 Dec 16–19; Washington.
59. Hadley JA. Value of short-course antimicrobial therapy in acute bacterial rhinosinusit. Intern J Antimicrob Agents 2005; 26 (Suppl. 3): S164–9.
60. Zervos M, Breen JD, Jorgensen D, Goodrich JM. Novel single-dose microsphere formulation of azithromycin versus levofloxacin for the treatment of acute exacerbation of chronic bronchitis. Infect Dis Clin Pract 2005; 13: 115–21.
61. D'Ignazio J, Camere MA, Levis DE et al. Novel single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother 2005; 49: 4035–41.
62. Drehobl MA, Salvo MC, Lewis DE, Breen JD. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community acquired pneumonia in adults. Chest 2005; 128: 2230–7.